Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future
Hakan Dogruel, Department of Internal Medicine, Antalya Ataturk State Hospital, Antalya 07040, Turkey
Mustafa Kemal Balci, Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Antalya 07070, Turkey
Author contributions: Dogruel H and Balci MK conceived of and designed the study; Dogruel H searched the literature and drafted the article; both authors revised the article and Balci MK gave final approval for the article.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mustafa Kemal, MD, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street, No. 100, Antalya 07070, Turkey. email@example.com
Telephone: +90-505-4789010 Fax: +90-242-2496040
Received: March 22, 2019
Peer-review started: March 22, 2019
First decision: May 31, 2019
Revised: June 13, 2019
Accepted: July 27, 2019
Article in press: July 27, 2019
Published online: August 15, 2019